Samsung Biologics Signs 58 Billion KRW Contract for Contract Manufacturing with US Biotech Company
[Asia Economy Reporter Moon Hyewon] Samsung Biologics announced on the 9th that it has signed a contract worth $51.45 million (approximately 57.9 billion KRW) for contract manufacturing organization (CMO) services with the US biopharmaceutical company FibroGen.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- Individual Investors Absorb Foreign Sell-Off... Concerns Over Becoming "Cannon Fodder" Emerge
- Experts Shocked by Record Numbers: "Just the Tip of the Iceberg" — The Identity Behind the 90% Dominating Teens [Chuiyakgukga]⑨
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
The contract period is from September 18 of this year to December 31, 2022.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Cheaper Than Mychew, but Nowhere to Be Found... Fears of a 'Pediatric Medical Crisis' as Drug Makers Halt Production [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/307/2026051910065268365_1779152813.jpg)
